A Patient with Axial Spondylarthritis Who Experienced Pancytopenia While Receiving Anti-TNF Therapy

Overview

Journal Clin Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2024 Jul 6

PMID 38970750

Authors

Sibel Suzen Ozbayrak

Nilgun Mesci

Merve Ozdemir Sezgin

Duygu Geler Kulcu

Affiliations

Soon will be listed here.

Abstract

Aplastic anemia is a rare and heterogeneous disease that causes pancytopenia and aplasia of the bone marrow. It is characterized by a failure of hematopoiesis. It is believed that approximately 65% of cases of acquired aplastic anemia are idiopathic. In a subset of cases, a drug or infection is the cause of bone marrow failure. This case report presents a 38-year-old patient with axial spondylarthritis who developed pancytopenia and was diagnosed with aplastic anemia during anti-TNF-α treatment.

References

Wronski J, Fiedor P . The Safety Profile of Tumor Necrosis Factor Inhibitors in Ankylosing Spondylitis: Are TNF Inhibitors Safer Than We Thought?. J Clin Pharmacol. 2018; 59(4):445-462. DOI: 10.1002/jcph.1348. View

Kozak N, Friedman J, Schattner A . Etanercept-associated transient bone marrow aplasia: a review of the literature and pathogenetic mechanisms. Drugs R D. 2014; 14(2):155-8. PMC: 4070464. DOI: 10.1007/s40268-014-0050-z. View

Li J, Zhang Z, Wu X, Zhou J, Meng D, Zhu P . Risk of Adverse Events After Anti-TNF Treatment for Inflammatory Rheumatological Disease. A Meta-Analysis. Front Pharmacol. 2021; 12:746396. PMC: 8591221. DOI: 10.3389/fphar.2021.746396. View

Bessissow T, Renard M, Hoffman I, Vermeire S, Rutgeerts P, Van Assche G . Review article: non-malignant haematological complications of anti-tumour necrosis factor alpha therapy. Aliment Pharmacol Ther. 2012; 36(4):312-23. DOI: 10.1111/j.1365-2036.2012.05189.x. View

Hastings R, Ding T, Butt S, Gadsby K, Zhang W, Moots R . Neutropenia in patients receiving anti-tumor necrosis factor therapy. Arthritis Care Res (Hoboken). 2010; 62(6):764-9. DOI: 10.1002/acr.20037. View

Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M . Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthritis Rheum. 2003; 48(4):1093-101. DOI: 10.1002/art.10885. View

Kuruvilla J, Leitch H, Vickars L, Galbraith P, Li C, Al-Saab S . Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. Eur J Haematol. 2003; 71(5):396-8. DOI: 10.1034/j.1600-0609.2003.00115.x. View

Dufour C, Giacchino R, Ghezzi P, Tonelli R, Ferretti E, Pitto A . Etanercept as a salvage treatment for refractory aplastic anemia. Pediatr Blood Cancer. 2008; 52(4):522-5. DOI: 10.1002/pbc.21886. View

Scott B, Ramakrishnan A, Fosdal M, Storer B, Becker P, Petersdorf S . Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. Br J Haematol. 2010; 149(5):706-10. PMC: 2931581. DOI: 10.1111/j.1365-2141.2010.08145.x. View

10.

Scott B, Ramakrishnan A, Storer B, Becker P, Petersdorf S, Estey E . Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept. Br J Haematol. 2010; 148(6):944-7. PMC: 2864317. DOI: 10.1111/j.1365-2141.2009.08061.x. View

11.

Deeg H, Jiang P, Holmberg L, Scott B, Petersdorf E, Appelbaum F . Hematologic responses of patients with MDS to antithymocyte globulin plus etanercept correlate with improved flow scores of marrow cells. Leuk Res. 2004; 28(11):1177-80. DOI: 10.1016/j.leukres.2004.03.016. View

12.

Tsimberidou A, Giles F . TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies. Expert Rev Anticancer Ther. 2002; 2(3):277-86. DOI: 10.1586/14737140.2.3.277. View

13.

Deeg H, Gotlib J, Beckham C, Dugan K, Holmberg L, Schubert M . Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study. Leukemia. 2002; 16(2):162-4. DOI: 10.1038/sj.leu.2402356. View

14.

Maciejewski J, Risitano A, Sloand E, Wisch L, Geller N, Barrett J . A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome. Br J Haematol. 2002; 117(1):119-26. DOI: 10.1046/j.1365-2141.2002.03381.x. View

15.

Rosenfeld C, Bedell C . Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome. Leuk Res. 2002; 26(8):721-4. DOI: 10.1016/s0145-2126(01)00201-6. View

16.

Mundle S, Venugopal P, Cartlidge J, Pandav D, Gezer S, Robin E . Indication of an involvement of interleukin-1 beta converting enzyme-like protease in intramedullary apoptotic cell death in the bone marrow of patients with myelodysplastic syndromes. Blood. 1996; 88(7):2640-7. View

17.

Shetty V, Mundle S, Alvi S, Showel M, Dar S, BOROK R . Measurement of apoptosis, proliferation and three cytokines in 46 patients with myelodysplastic syndromes. Leuk Res. 1996; 20(11-12):891-900. DOI: 10.1016/s0145-2126(96)00008-2. View

18.

Raza A, Gezer S, Mundle S, Gao X, Alvi S, BOROK R . Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood. 1995; 86(1):268-76. View

19.

Dincol G, Aktan M, Diz-Kucukkaya R, Yavuz S, Nalcaci M, Ozturk S . Treatment of acquired severe aplastic anemia with antilymphocyte globulin, cyclosporin A, methyprednisolone, and granulocyte colony-stimulating factor. Am J Hematol. 2007; 82(9):783-6. DOI: 10.1002/ajh.20954. View

20.

Peslak S, Olson T, Babushok D . Diagnosis and Treatment of Aplastic Anemia. Curr Treat Options Oncol. 2017; 18(12):70. PMC: 5804354. DOI: 10.1007/s11864-017-0511-z. View